- TheStreet.com•2 days ago
This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.
- American City Business Journals•4 days ago
Lexington-based Concert Pharmaceuticals rebuffed a $250 million buyout offer from Vertex Pharmaceuticals in November before ultimately striking a deal earlier this month to sell a cystic fibrosis drug to the Boston company for $160 million, according to a federal filing. Under the agreement, Vertex is slated to acquire the 69-employee biotech’s cystic fibrosis drug, CTP-656, a reformulation of Vertex’s approved treatment Kalydeco.
- American City Business Journals•11 days ago
The top-performing public biotech in Massachusetts over the past year is located in a nondescript brick building with no signage, located along a stretch of highway in Norwood that is better known for its car dealerships than drug developers. Investors in Corbus Pharmaceuticals (CRBP) don’t much seem to mind. The company believes that its anti-inflammatory treatment — initially under the generic name of "resunab" but recently renamed "anabasum" — could treat several rare disorders.
VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Bid||89.20 x 100|
|Ask||92.46 x 100|
|Day's Range||88.90 - 91.49|
|52 Week Range||71.46 - 103.73|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-197.39|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|